Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sanjeev Forsyth"'
Autor:
Macarena I de la Fuente, Howard Colman, Mark Rosenthal, Brian A Van Tine, Danijela Levacic, Tobias Walbert, Hui K Gan, Maria Vieito, Mohammed M Milhem, Kathryn Lipford, Sanjeev Forsyth, Sylvie M Guichard, Yelena Mikhailov, Alexander Sedkov, Julie Brevard, Patrick F Kelly, Hesham Mohamed, Varun Monga
Publikováno v:
Scientia
Background Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b253bb132081b03fc3679216acf7f5
https://doi.org/10.1093/neuonc/noac139
https://doi.org/10.1093/neuonc/noac139
Autor:
Justin M, Watts, Maria R, Baer, Jay, Yang, Thomas, Prebet, Sangmin, Lee, Gary J, Schiller, Shira N, Dinner, Arnaud, Pigneux, Pau, Montesinos, Eunice S, Wang, Karen P, Seiter, Andrew H, Wei, Stephane, De Botton, Montserrat, Arnan, Will, Donnellan, Anthony P, Schwarer, Christian, Récher, Brian A, Jonas, P Brent, Ferrell, Christophe, Marzac, Patrick, Kelly, Jennifer, Sweeney, Sanjeev, Forsyth, Sylvie M, Guichard, Julie, Brevard, Patrick, Henrick, Hesham, Mohamed, Jorge E, Cortes
Publikováno v:
The Lancet. Haematology. 10(1)
Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd7ab69b54ec81a079a6a6e2d477c51
https://pubmed.ncbi.nlm.nih.gov/36566049
https://pubmed.ncbi.nlm.nih.gov/36566049
Autor:
Macarena I, de la Fuente, Howard, Colman, Mark, Rosenthal, Brian A, Van Tine, Danijela, Levacic, Tobias, Walbert, Hui K, Gan, Maria, Vieito, Mohammed M, Milhem, Kathryn, Lipford, Sanjeev, Forsyth, Sylvie M, Guichard, Yelena, Mikhailov, Alexander, Sedkov, Julie, Brevard, Patrick F, Kelly, Hesham, Mohamed, Varun, Monga
Publikováno v:
Neuro-oncology.
Olutasidenib (FT2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::32e6ebd70c69fd59005b777face6583f
https://pubmed.ncbi.nlm.nih.gov/35639513
https://pubmed.ncbi.nlm.nih.gov/35639513
Autor:
Santosh L. Saraf, Patrick Kelly, Theodosia A. Kalfa, Marilyn J. Telen, Modupe Idowu, Patricia Schroeder, James Geib, Kimberly Cruz, R. Clark Brown, Sanjeev Forsyth, Eric Q. Wu
Publikováno v:
Blood. 138:9-9
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR), that increases PKR activity, resulting in decreased 2,3-DPG and increased ATP in red blood cells (RBCs) of healthy volunteers (HV) and patients (pts) with sickle cell dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0fce9c947e441ecfe5e8d335ccf9156
https://doi.org/10.1182/blood-2021-147091
https://doi.org/10.1182/blood-2021-147091
Autor:
Santosh L. Saraf, Patrick Kelly, Frans A. Kuypers, Patricia Schroeder, Eric Q. Wu, Sanjeev Forsyth, Theodosia A. Kalfa, Renae Mayer, Marilyn J. Telen, Punam Malik, Mark Lerman, Luke R. Smart, Jeremie H. Estepp, Kimberly Cruz, Maria D. Ribadeneira, R. Clark Brown
Publikováno v:
Blood. 136:19-20
I NTRODUCTION: The hallmark of sickle cell disease (SCD) is hemoglobin S (HbS) polymerization upon deoxygenation, resulting in red blood cell (RBC) sickling, oxidative damage, membrane damage, hemolysis, cell adhesion, and vaso-occlusion. Exacerbatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1cf42e524e00d46570afb00e1e37038
https://doi.org/10.1182/blood-2020-134269
https://doi.org/10.1182/blood-2020-134269
Autor:
Maria Ribadeneira, Lili Yao, Paul Ehrlich, Angela Toms, Sylvie Guichard, Sanjeev Forsyth, Blythe Thomson
Publikováno v:
Neuro Oncol
BACKGROUND Iocitrate dehydrogenase mutations (mIDH1) are present in >70% of patients with Grade II/III gliomas resulting in production and accumulation of (R)-2-hydroxyglutarate (2-HG) causing DNA hypermethylation and promoting tumorigenesis. This ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a628c47b58cca650a0d64393a8f0662
https://europepmc.org/articles/PMC6845728/
https://europepmc.org/articles/PMC6845728/
Autor:
Sylvie Guichard, Sanjeev Forsyth, Danijela Levaci, Macarena I. de la Fuente, Mohammed M. Milhem, Patrick Kelly, Mark Rosenthal, Tobias Walbert, Yelena Mikhailov, Hui K Gan, Maria Vieito, Kate Lipford, Blythe Thomson, Brian A. Van Tine, Varun Monga, Howard Colman, Alexander Sedkov
Publikováno v:
Journal of Clinical Oncology. 38:2505-2505
2505 Background: Isocitrate dehydrogenase 1 mutations (mIDH1) are present in >70% of patients with Grade II/III gliomas resulting in production and accumulation of (R)-2-hydroxyglutarate causing DNA hypermethylation and promoting tumorigenesis. Oluta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95619919f2e148c88ea7af75ef7c0371
https://doi.org/10.1200/jco.2020.38.15_suppl.2505
https://doi.org/10.1200/jco.2020.38.15_suppl.2505
Autor:
Antoine Italiano, Yelena Mikhailov, Patrick Kelly, Kate Lipford, Mark Rosenthal, Brian A. Van Tine, Sanjeev Forsyth, Jean-Yves Blay, Sylvie Guichard, John A. Charlson, Florence Duffaud, Robin L. Jones, Macarena I. de la Fuente, Madappa N. Kundranda, Blythe Thomson, Lipika Goyal, Christophe Massard, Teresa Macarulla, Patricia Roxburgh, Changhoon Yoo
Publikováno v:
Journal of Clinical Oncology. 38:e16643-e16643
e16643 Background: Isocitrate dehydrogenase 1 mutations (mIDH1) are present in a variety of solid tumors resulting in production and accumulation of (R)-2-hydroxyglutarate causing DNA hypermethylation and promoting tumorigenesis. Olutasidenib is an o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6938eed78f219af51f2668b0aaf984
https://doi.org/10.1200/jco.2020.38.15_suppl.e16643
https://doi.org/10.1200/jco.2020.38.15_suppl.e16643
Autor:
Patrick Henrick, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Thomas Prebet, Julie Brevard, M. Arnan, J. Yang, Maria R. Baer, William B. Donnellan, Shira Dinner, A. Wei, Hesham Mohamed, Gary J. Schiller, S. Lee, Sanjeev Forsyth, Jennifer Sweeney, E.S. Wang, Patrick Kelly, Paul Brent Ferrell, Pau Montesinos
Publikováno v:
HemaSphere. 3:86-87
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::817c6bb589647f99cedce2828cc7afe6
https://doi.org/10.1097/01.hs9.0000559288.11309.57
https://doi.org/10.1097/01.hs9.0000559288.11309.57
Autor:
Patricia Schroeder, Olga Polyanskaya, Diamantis G. Konstantinidis, Lindsey Wilson, Adam Drake, Theodosia A. Kalfa, Santosh L. Saraf, Marilyn J. Telen, Punam Malik, Lukasz Biernat, Jeremy H. Estepp, Sanjeev Forsyth, Patrick Kelly, Frans A. Kuypers, Maria D. Ribadeneira, Hyon J. Kim
Publikováno v:
Blood. 134:616-616
Background: The hallmark of sickle cell disease (SCD) is hemoglobin S (HbS) polymerization upon deoxygenation, resulting in red blood cell (RBC) sickling, oxidative damage, membrane damage, hemolysis, chronic anemia, vaso-occlusions and inflammation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14f9ffb21ca2d460390da732bce8a434
https://doi.org/10.1182/blood-2019-121889
https://doi.org/10.1182/blood-2019-121889